NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT01049243,A Study Evaluating the Efficacy of Fluocinonide Cream 0.1% (Vanos) in Subjects With Atopic Dermatitis,https://clinicaltrials.gov/study/NCT01049243,Vanos,COMPLETED,The purpose of this research study is to better understand how fluocinonide cream 0.1% (VanosÂ®) works when people use it to treat atopic dermatitis for just a few days.,YES,Atopic Dermatitis,DRUG: Fluocinonide Cream 0.1%,"Change in Investigator Global Assessment of Atopic Dermatitis Severity From Baseline to Day 2/3., Use of the Investigator's Global Assessment (IGA) score, a subjective scale measuring disease severity. Based on a 6-point scale from 0 (completely clear) to 5 (very severe). Defined score of 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, 4 = severe., Baseline to 3 days","Change in Investigator Global Assessment of Atopic Dermatitis Severity From Baseline to Day 14., Use of the Investigator's Global Assessment (IGA) score, a subjective scale measuring disease severity. Based on a 6-point scale from 0 (completely clear) to 5 (very severe). Defined score of 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, 4 = severe., Baseline to 14 days",,Wake Forest University Health Sciences,Medicis Pharmaceutical Corporation,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE4,20,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,IRB00006468,2009-03,2009-09,2009-10,2010-01-14,2012-12-21,2018-08-01,"Wake Forest University Health Sciences, Winston-Salem, North Carolina, 27157, United States",
